United Therapeutics (NASDAQ:UTHR) Director Christopher Causey Sells 1,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 1,000 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $500.01, for a total transaction of $500,010.00. Following the transaction, the director owned 4,190 shares in the company, valued at approximately $2,095,041.90. The trade was a 19.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Price Performance

Shares of UTHR stock opened at $489.69 on Tuesday. The company has a fifty day moving average price of $479.72 and a two-hundred day moving average price of $397.27. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $519.99. The stock has a market cap of $21.09 billion, a P/E ratio of 18.56, a P/E/G ratio of 4.77 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the prior year, the firm earned $6.39 EPS. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Darwin Global Management Ltd. bought a new stake in United Therapeutics in the 3rd quarter valued at about $317,617,000. Norges Bank acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $136,453,000. Invesco Ltd. raised its holdings in United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares in the last quarter. AQR Capital Management LLC lifted its position in United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares during the period. Finally, Assetmark Inc. lifted its holdings in shares of United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after acquiring an additional 197,384 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on UTHR. HC Wainwright lifted their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 29th. Finally, UBS Group lifted their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.